INTRODUCTION
Psoriasis is a chronic skin condition with a negative impact on patient quality of life. The National Psoriasis Foundation states that an acceptable response to psoriasis treatment is at least a 75% reduction in body surface area (BSA) at 3 months after initiation of treatment.1 This reduction in BSA has been associated with improvement in quality of life, with clearance rates of clear to almost clear leading to an even greater improvement in quality of life.2,3 To date, there have been no studies examining the relationship between improvement in quality of life following a reduction in BSA, and the increased utilization of cosmetic procedures. Here, we examine the relationship between quality of life and the use of various cosmetic procedures in patients treated for psoriasis with systemic and biologic therapies who achieved at least 75% reduction in BSA.
METHODS
This was a retrospective study assessing quality of life and the use of cosmetic procedures in psoriasis patients after attaining a75% or greater reduction of the body surface area with biologic agents only, systemic agents only, or a combination of both. This study was conducted according to the ethical guidelines of the 1975 Declaration of Helsinki. All patients provided informed consent.
A chart review was conducted at a single dermatology center (Dermatology Institute and Skin Care Center, Santa Monica CA) and 138 patients were included in this study. All patients surveyed had a history of moderate to severe psoriasis, had attained 75% or greater BSA reduction with biologic agents or oral systemic therapies, and had undergone at least one cosmetic procedure in the past 2 years. Patient characteristics were collected including age, sex, present BSA at time of survey, history of treatment with biologic or oral systemic therapies, and types of cosmetic procedures undergone.
Patients completed the Dermatology Life Quality Index (DLQI)
A chart review was conducted at a single dermatology center (Dermatology Institute and Skin Care Center, Santa Monica CA) and 138 patients were included in this study. All patients surveyed had a history of moderate to severe psoriasis, had attained 75% or greater BSA reduction with biologic agents or oral systemic therapies, and had undergone at least one cosmetic procedure in the past 2 years. Patient characteristics were collected including age, sex, present BSA at time of survey, history of treatment with biologic or oral systemic therapies, and types of cosmetic procedures undergone.
Patients completed the Dermatology Life Quality Index (DLQI)